1. Protein Tyrosine Kinase/RTK
  2. VEGFR
  3. Efdamrofusp alfa

Efdamrofusp alfa 是一种双特异性融合蛋白。Efdamrofusp alfa 能够中和 VEGF 亚型和 C3b/C4b。Efdamrofusp alfa 可用于新生血管性年龄相关性黄斑变性 (nAMD) 和其他与补体相关的眼部疾病的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Efdamrofusp alfa Chemical Structure

Efdamrofusp alfa Chemical Structure

CAS No. : 2375661-82-6

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
1 mg   询价  
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 1 篇科研文献

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions[1].

体外研究
(In Vitro)

Efdamrofusp alfa (0.135 mg/mL; 0, 6, 12, or 24 h) suppresses endothelial cell migration and tube formation[1].
Efdamrofusp alfa (0-1000 μg/mL) inhibits complement activation in vitro[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay [1]

Cell Line: Human primary umbilical vein endothelial cell (HUVEC)
Concentration: 0.135 mg/mL
Incubation Time: 0, 6, 12, or 24 h
Result: Showed a 20.91% reduction in migration.
体内研究
(In Vivo)

Efdamrofusp alfa (13.5 μg; 3 days) inhibits activation ofthe complement system in a mouse model oflaser-induced CNV[1].
Efdamrofusp alfa (1.35 mg; single intravitreal injection) shows favorable safety profiles and exhibited antiangiogenetic efficacy in a nonhuman primate laser-induced CNV model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice[1]
Dosage: 13.5 μg; 13.0 μg
Administration: 3 days; 7days
Result: Significantly reduced C3d deposition.
Reduced vascular leakage at 7 days after laser-induced injury.
Significantly suppressed CNV formation 7 days after laser-induced injury.
Reduced the concentrations of vitreous VEGF-A.
Animal Model: Rhesus monkeys[1]
Dosage: 1.35 mg
Administration: Single intravitreal injection
Result: Decreased the CNV leakage at 14 and 28 days and effectively reduced CNV volume 28 days.
CAS 号
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献

Efdamrofusp alfa 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Efdamrofusp alfa
目录号:
HY-P99905
需求量: